Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
CMOC to Acquire Equinox Gold’s Brazilian Mines in $1 Billion Deal to Expand Precious Metals Portfolio 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
BURLINGTON, Mass., Dec. 04, 2015 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, will present at the Oppenheimer 26th Annual Healthcare Conference on Tuesday, December 8, 2015 at 9:45 a.m. Eastern Time at the Westin Grand Central Hotel in New York City.
To access the live webcast and subsequent archived recordings for the presentation, please visit the Flexion website at http://flexiontherapeutics.com/.
About Flexion Therapeutics
Flexion is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel pain therapies. The company is currently advancing a portfolio of local, injectable, non-opioid drug candidates that have the potential to provide better and more persistent analgesia compared with existing therapy. The company's lead product candidate, Zilretta™, has been designed to provide improved analgesic therapy for the five million patients who receive intra-articular (IA) injections for osteoarthritis (OA) of the knee annually. The company also has two additional product candidates, FX007, a locally administered TrkA receptor antagonist for post-operative pain, and FX005, an IA, sustained-release p38 MAP kinase inhibitor for end-stage OA patients.
CONTACTS: Investor Relations Contact David Carey Lazar Partners LTD T: 212-867-1768 [email protected] Media Relations Contact Mariann Caprino TogoRun 917.242.1087 [email protected] Corporate Contact Fred Driscoll Chief Financial Officer Flexion Therapeutics, Inc. T: 781-305-7763 [email protected]
